Literature DB >> 27199067

Pharmacokinetics and Pharmacodynamics of Dabigatran 75 mg b.i.d. in Patients With Severe Chronic Kidney Disease.

Judith Kooiman, Tom van der Hulle, Hugo Maas, Sabrina Wiebe, Stephan Formella, Andreas Clemens, Marjolijn van Buren, Martien Janssen, Ton J Rabelink, Menno V Huisman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27199067     DOI： 10.1016/j.jacc.2016.03.516

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN： 0735-1097            Impact factor:   24.094


× No keyword cloud information.
  9 in total

Review 1.  Direct oral anticoagulants in patients with atrial fibrillation and renal impairment, extremes in weight, or advanced age.

Authors:  Leo F Buckley; Eva Rybak; Ahmed Aldemerdash; Judy W M Cheng; John Fanikos
Journal:  Clin Cardiol       Date:  2016-10-07       Impact factor: 2.882

2.  A Comprehensive Whole-Body Physiologically Based Pharmacokinetic Model of Dabigatran Etexilate, Dabigatran and Dabigatran Glucuronide in Healthy Adults and Renally Impaired Patients.

Authors:  Daniel Moj; Hugo Maas; André Schaeftlein; Nina Hanke; José David Gómez-Mantilla; Thorsten Lehr
Journal:  Clin Pharmacokinet       Date:  2019-12       Impact factor: 6.447

3.  Clinical Pharmacology of Oral Anticoagulants in Patients with Kidney Disease.

Authors:  Nishank Jain; Robert F Reilly
Journal:  Clin J Am Soc Nephrol       Date:  2018-05-25       Impact factor: 8.237

Review 4.  Defibrillation Testing During ICD Implantation - Should we or Should we Not?

Authors:  Justin Hayase; Noel G Boyle
Journal:  J Atr Fibrillation       Date:  2017-02-28

Review 5.  The Nonvitamin K Antagonist Oral Anticoagulants and Atrial Fibrillation: Challenges and Considerations.

Authors:  Anna Plitt; Sameer Bansilal
Journal:  J Atr Fibrillation       Date:  2017-02-28

6.  Chronic kidney disease and arrhythmias: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.

Authors:  Mintu P Turakhia; Peter J Blankestijn; Juan-Jesus Carrero; Catherine M Clase; Rajat Deo; Charles A Herzog; Scott E Kasner; Rod S Passman; Roberto Pecoits-Filho; Holger Reinecke; Gautam R Shroff; Wojciech Zareba; Michael Cheung; David C Wheeler; Wolfgang C Winkelmayer; Christoph Wanner
Journal:  Eur Heart J       Date:  2018-06-21       Impact factor: 29.983

Review 7.  Pharmacological and Non-pharmacological Treatments for Stroke Prevention in Patients with Atrial Fibrillation.

Authors:  Laura Ueberham; Nikolaos Dagres; Tatjana S Potpara; Andreas Bollmann; Gerhard Hindricks
Journal:  Adv Ther       Date:  2017-09-27       Impact factor: 3.845

8.  Relationship between the degree of renal dysfunction and the safety and efficacy outcomes in patients with atrial fibrillation receiving direct oral anticoagulants.

Authors:  Ryo Wada; Masaya Shinohara; Rine Nakanishi; Toshio Kinosihita; Hitomi Yuzawa; Takanori Ikeda
Journal:  J Arrhythm       Date:  2021-01-04

9.  Retrospective Comparison of Patients ≥ 80 Years With Atrial Fibrillation Prescribed Either an FDA-Approved Reduced or Full Dose Direct-Acting Oral Anticoagulant.

Authors:  Roy Taoutel; Michael D Ezekowitz; Usman A Chaudhry; Carly Weber; Dana Hassan; Ed J Gracely; Mohammed H Kamareddine; Benjamin I Horn; Glenn R Harper
Journal:  Int J Cardiol Heart Vasc       Date:  2022-10-10
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.